Reassessing Biomarkers: Guiding Second-Line Therapy in Upper GI Cancer

Opinion
Video

Experts discuss how biomarker testing results should be reassessed or expanded upon disease progression and how they guide the selection of second-line therapies or clinical trial enrollment.

Video content above is prompted by the following:

  • How should biomarker testing results be reassessed or expanded upon disease progression, and how do they guide the selection of second-line therapies or clinical trial enrollment?
Recent Videos
5 experts in this video
5 experts in this video
Related Content